May 23, 2017 09:44 AM EDT

AstraZeneca cheers a success for PhIII benralizumab study; TP raises $45M for cancer drug

Shehla Shakoor

Managing Director

→ AstraZeneca says that its Phase III ZONDA study of benralizumab hit the primary endpoint, allowing asthma patients to reduce the use of steroids …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca cheers a success for PhIII benralizumab study; TP raises $45M for cancer drug

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

At Jefferies, all that manufacturers want to talk about is GLP-1s

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?

As­traZeneca cheers a suc­cess for PhI­II ben­ral­izum­ab study; TP rais­es $45M for can­cer drug

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

AstraZeneca cheers a success for PhIII benralizumab study; TP raises $45M for cancer drug

Patient dies in Neurogene's Rett syndrome study

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

At Jefferies, all that manufacturers want to talk about is GLP-1s

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?